sra-28 Antibody

Basic Structure and Function of SRA

SRA belongs to the pattern recognition receptor family and recognizes a broad spectrum of ligands including acetylated low-density lipoprotein (Ac-LDL), polyribonucleotide I, and various polysaccharides . The receptor plays a crucial role in both innate and adaptive immunity, with its expression primarily localized to cells of myeloid lineage. SRA antibodies have become essential tools for investigating these functions across multiple research applications, from basic immunophenotyping to advanced therapeutic development.

Types of SRA Antibodies Used in Research

SRA antibodies used in research settings include monoclonal antibodies like D-8 (a mouse monoclonal IgM antibody) , which are employed for various applications including immunohistochemistry, flow cytometry, and Western blotting. These antibodies recognize specific epitopes on the SRA protein and serve as invaluable tools for detecting SRA expression and studying its biological functions in experimental settings.

Detection of SRA Expression in Cell Populations

SRA antibodies are commonly used to detect and quantify SRA expression in various cell populations, particularly macrophages and dendritic cells. This application is fundamental in studies investigating immune cell phenotypes in different physiological and pathological conditions. Flow cytometry using fluorescently labeled anti-SRA antibodies allows researchers to identify SRA-expressing cells within heterogeneous populations and quantify expression levels.

For example, in studies of tumor microenvironments, SRA antibodies have been used to identify tumor-associated macrophages and correlate SRA expression with disease progression . This approach provides valuable insights into the role of SRA-expressing cells in tumor development and potential therapeutic targeting.

Immunohistochemical Analysis of Tissue Samples

SRA antibodies are frequently employed in immunohistochemistry (IHC) to detect SRA expression in tissue sections. This application enables researchers to visualize the distribution and relative abundance of SRA-expressing cells within complex tissue architectures. In pathological studies, IHC using SRA antibodies helps identify changes in SRA expression patterns associated with disease states.

When performing IHC with SRA antibodies, researchers typically use standard protocols involving tissue fixation, antigen retrieval, primary antibody incubation (with the SRA antibody), followed by detection systems such as horseradish peroxidase-conjugated secondary antibodies or fluorescently labeled secondary antibodies. This approach allows for both qualitative assessment of SRA expression and semi-quantitative analysis through digital image analysis.

Investigating SRA's Role in T Cell Activation

Research has demonstrated SRA's immunosuppressive role in T cell activation, making SRA antibodies valuable tools for studying these interactions. In experimental settings, SRA antibodies can be used to detect SRA expression on dendritic cells and correlate this expression with T cell responses .

A notable experimental approach involves the use of dendritic cell-T cell co-culture assays, where SRA-expressing dendritic cells are used to stimulate antigen-specific T cells. In these assays, researchers can measure T cell activation markers, such as IL-2 production, to assess the immunosuppressive effects of SRA. For example, research has shown that SRA-expressing dendritic cells suppress T cell activation, and this suppression can be reversed by SRA inhibitors like rhein .

SRA Antibodies in Cancer Immunotherapy Research

SRA antibodies have significant applications in cancer immunotherapy research due to SRA's role in suppressing antitumor immune responses. Studies have shown that SRA expression is upregulated in tumor-associated immune cells and correlates with poor treatment outcomes .

In experimental settings, researchers use SRA antibodies to:

• Identify SRA-expressing cells within the tumor microenvironment

• Correlate SRA expression with tumor progression and treatment response

• Evaluate the effects of SRA inhibition on antitumor immune responses

• Develop strategies to target SRA-expressing cells as part of immunotherapeutic approaches

Research has indicated that pharmacological inhibition of SRA function may provide therapeutic benefits in cancer treatment by enhancing antitumor immune responses . This makes SRA antibodies essential tools for developing and evaluating such therapeutic approaches.

Advanced Flow Cytometry Applications

For advanced flow cytometry applications, SRA antibodies can be used in multi-parameter analyses to characterize complex immune cell populations. This approach involves staining cells with multiple antibodies, including anti-SRA, each labeled with different fluorochromes.

As demonstrated in research protocols, cells can be labeled with biotinylated target antigens (such as PD-L1), followed by detection with fluorophore-conjugated streptavidin and additional antibodies against cell surface markers . This approach allows researchers to simultaneously assess multiple parameters, including SRA expression, antigen binding, and other cellular characteristics.

Optimization of SRA Antibody Staining Protocols

When using SRA antibodies for research applications, optimization of staining protocols is essential for obtaining reliable and reproducible results. Key considerations include:

For flow cytometry applications specifically, researchers typically label cells with anti-SRA antibodies along with other markers of interest, followed by appropriate secondary detection reagents . For example, in studies involving yeast surface display systems, cells are labeled with target antigens and antibodies, followed by detection with fluorophore-conjugated secondary reagents .

Troubleshooting SRA Antibody Applications

Common challenges in SRA antibody applications and their solutions include:

• Low signal intensity:

  • Increase antibody concentration

  • Extend incubation time

  • Optimize fixation and permeabilization conditions (if applicable)

  • Ensure proper antigen retrieval (for IHC)

• High background or nonspecific staining:

  • Increase blocking time or concentration

  • Reduce antibody concentration

  • Include additional washing steps

  • Use more specific detection systems

• Inconsistent results:

  • Standardize sample preparation procedures

  • Maintain consistent incubation times and temperatures

  • Prepare fresh reagents regularly

  • Include appropriate controls in each experiment

• Cross-reactivity:

  • Use more specific antibody clones

  • Include additional blocking steps

  • Validate antibody specificity with appropriate controls

Using SRA Antibodies in Inhibitor Screening Assays

SRA antibodies play a crucial role in evaluating the efficacy of SRA inhibitors, which have potential applications in cancer therapy. Research has identified small molecule inhibitors of SRA, such as rhein, that can reverse SRA's immunosuppressive effects .

In experimental settings, researchers use SRA antibodies to:

• Confirm SRA expression in target cells

• Evaluate the effects of potential inhibitors on SRA function

• Assess changes in SRA-mediated signaling pathways

For example, in studies evaluating rhein as an SRA inhibitor, researchers used SRA-expressing dendritic cells to stimulate T cell activation and measured IL-2 production as an indicator of T cell activation . The results showed that rhein significantly enhanced T cell activation in wild-type cells but had no effect in SRA-deficient cells, confirming that its effects were specifically mediated through SRA inhibition .

Evaluating SRA in Immune Signaling Pathways

SRA antibodies are valuable tools for investigating SRA's role in immune signaling pathways. Research has shown that SRA mediates responses to various ligands, including polyinosinic:polycytidylic acid (poly(I:C)), which activates transcription factors such as interferon regulatory factor 3 (IRF3) and signal transducer and activator of transcription 1 (STAT1) .

In experimental approaches, researchers use SRA antibodies to identify SRA-expressing cells and correlate SRA expression with signaling pathway activation. Studies have demonstrated that SRA inhibitors like rhein can block poly(I:C)-induced activation of IRF3 and STAT1, indicating their potential utility in modulating immune responses .

SRA Antibodies in Therapeutic Development

Current research is exploring the potential of targeting SRA as a therapeutic strategy in cancer treatment. SRA antibodies are essential tools in this research, enabling the identification of SRA-expressing cells and evaluation of therapeutic approaches targeting SRA function.

Research has demonstrated that SRA expression correlates with poor treatment outcomes in cancer patients, suggesting that targeting SRA may enhance the efficacy of cancer therapies . Studies using SRA inhibitors have shown promising results in enhancing T cell activation and potentially improving antitumor immune responses .

Future Applications of SRA Antibodies in Research

Future research directions for SRA antibodies include:

• Development of more specific and sensitive SRA antibodies for research applications

• Application of SRA antibodies in high-throughput screening of potential SRA inhibitors

• Utilization of SRA antibodies in combination with other markers for comprehensive characterization of immune cell populations in disease states

• Integration of SRA antibody-based assays with advanced imaging and single-cell analysis techniques

These advancements will further enhance our understanding of SRA's biological functions and its potential as a therapeutic target in various diseases.

Selection of Appropriate SRA Antibody Clones

The selection of appropriate SRA antibody clones is critical for successful research applications. Different clones may recognize distinct epitopes on the SRA protein, which can affect their utility in specific applications. When selecting an SRA antibody, researchers should consider:

• The specific application (flow cytometry, IHC, Western blotting, etc.)

• The species of origin and cross-reactivity

• The isotype and detection requirements

• Validation data for the specific application

For example, the D-8 clone (a mouse monoclonal IgM antibody) has specific applications and detection requirements that should be considered when designing experiments.

Quantitative Analysis in SRA Expression Studies

For quantitative analysis of SRA expression, researchers should consider the following methodological approaches:

• Flow cytometry with calibration beads for absolute quantification

• Relative quantification using mean fluorescence intensity (MFI) values

• Western blotting with densitometric analysis

• qPCR for mRNA expression analysis

In flow cytometry applications, researchers typically analyze SRA expression by calculating the percentage of SRA-positive cells and/or the MFI values, which provide information about the relative expression levels per cell . These quantitative approaches enable more rigorous analysis of SRA expression patterns and their correlation with biological phenomena.